This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Collectively, this joint portfolio aims to boost clinicians’ confidence in imageinterpretation to support diagnosis, treatment planning, and monitoring, while supporting consistent and efficient workflows.
Precision PET imaging with POSLUMA can help identify the location and extent of prostate cancer, providing clinically valuable information to guide patient management. A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer.
A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer. from October 1 to 4, 2023.
Nationally recognized clinical oncology guidelines for prostate cancer now include POSLUMA, alongside and for all the same categories as the other currently FDA-approved PSMA PET radiopharmaceuticals.” PET in Men with Newly Diagnosed High-risk Prostate Cancer and Negative Conventional Imaging, ” by Phillip H.
tesla MRI AI body composition analysis Cardiac PET Cryo/thermoablation CT colonography Genicular artery embolization Hyperpolarized xenon-129 MRI PET/MRI Photon-counting CT Radiomics Theranostics Whole-body MRI screening Image of the Year 3D PET/MR image.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content